Major Depressive Disorder - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：200頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Major Depressive Disorder - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2014’, provides an overview of the Major Depressive Disorder’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2014’, provides an overview of the Major Depressive Disorder’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Major Depressive Disorder Overview 9
Therapeutics Development 10
Pipeline Products for Major Depressive Disorder - Overview 10
Pipeline Products for Major Depressive Disorder - Comparative Analysis 11
Major Depressive Disorder - Therapeutics under Development by Companies 12
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 16
Major Depressive Disorder - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Major Depressive Disorder - Products under Development by Companies 22
Major Depressive Disorder - Products under Investigation by Universities/Institutes 26
Major Depressive Disorder - Companies Involved in Therapeutics Development 27
Johnson & Johnson 27
F. Hoffmann-La Roche Ltd. 28
AstraZeneca PLC 29
Eli Lilly and Company 30
Alkermes Plc 31
Dainippon Sumitomo Pharma Co., Ltd. 32
Taisho Pharmaceutical Co., Ltd. 33
Neurocrine Biosciences, Inc. 34
Richter Gedeon Nyrt. 35
H. Lundbeck A/S 36
OPKO Health, Inc. 37
Neuralstem, Inc. 38
Suven Life Sciences Ltd. 39
e-Therapeutics plc 40
Intas Pharmaceuticals Ltd. 41
Angelini Group 42
Fabre-Kramer Pharmaceuticals, Inc. 43
Dart NeuroScience LLC 44
M's Science Corporation 45
BrainCells Inc. 46
Otsuka Holdings Co., Ltd. 47
Reviva Pharmaceuticals Inc. 48
Luye Pharma Group Ltd. 49
Euthymics Bioscience, Inc. 50
Naurex, Inc. 51
PharmaNeuroBoost NV 52
NeurOp Corporation 53
Edgemont Pharmaceuticals, LLC 54
Methylation Sciences Inc. 55
Sunovion Pharmaceuticals Inc. 56
BRAINco Biopharma, S.L. 57
Bionure 58
Cerecor Inc. 59
nLife Therapeutics, S.L. 60
Aniona ApS 61
Major Depressive Disorder - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 72
Assessment by Molecule Type 75
Drug Profiles 78
vortioxetine - Drug Profile 78
vortioxetine - Drug Profile 80
lurasidone hydrochloride - Drug Profile 82
brexpiprazole - Drug Profile 84
cariprazine - Drug Profile 86
TGFK-07AD - Drug Profile 88
(pipamperone + citalopram) - Drug Profile 89
INASTR-001 - Drug Profile 91
trazodone hydrochloride - Drug Profile 92
(aripiprazole + sertraline) - Drug Profile 93
amitifadine - Drug Profile 95
Rellidep - Drug Profile 97
edivoxetine - Drug Profile 98
verucerfont - Drug Profile 100
RG-1578 - Drug Profile 102
TGBA-01AD - Drug Profile 104
SCH-900978 - Drug Profile 105
tramadol - Drug Profile 106
RG-7090 - Drug Profile 108
cutamesine - Drug Profile 109
GLYX-13 - Drug Profile 111
CERC-301 - Drug Profile 113
(samidorphan + buprenorphine hydrochloride) - Drug Profile 114
LY-2940094 - Drug Profile 115
HT-2157 - Drug Profile 116
esketamine - Drug Profile 117
MSI-195 - Drug Profile 118
diazoxide - Drug Profile 119
tedatioxetine - Drug Profile 120
BCI-632 - Drug Profile 122
AN-788 - Drug Profile 124
NSI-189 - Drug Profile 125
DSP-1053 - Drug Profile 126
BCI-838 - Drug Profile 127
BCI-1038 - Drug Profile 129
BCI-1206 - Drug Profile 130
BCI-1283 - Drug Profile 131
NRX-1074 - Drug Profile 132
SEP-363856 - Drug Profile 133
LY-03005 - Drug Profile 134
NSI-189 - Drug Profile 135
NRX-1050 - Drug Profile 136
SUVN-911 - Drug Profile 137
NR2B Program For Major Depression - Drug Profile 138
NLF-NEU - Drug Profile 139
Major Depression Program - Drug Profile 140
BN-201 - Drug Profile 141
Ketamine Metabolites - Drug Profile 142
BN-204 - Drug Profile 143
BN-206 - Drug Profile 144
RP-5063 - Drug Profile 145
EDG-005 - Drug Profile 146
Drug For Depression - Drug Profile 147
BN-205 - Drug Profile 148
Major Depressive Disorder - Recent Pipeline Updates 149
Major Depressive Disorder - Dormant Projects 177
Major Depressive Disorder - Discontinued Products 182
Major Depressive Disorder - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 196
Disclaimer 196
List of Tables
Number of Products under Development for Major Depressive Disorder, H1 2014 14
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Comparative Analysis by Unknown Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Development by Companies, H1 2014 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2014 30
Major Depressive Disorder - Pipeline by Johnson & Johnson, H1 2014 31
Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 32
Major Depressive Disorder - Pipeline by AstraZeneca PLC, H1 2014 33
Major Depressive Disorder - Pipeline by Eli Lilly and Company, H1 2014 34
Major Depressive Disorder - Pipeline by Alkermes Plc, H1 2014 35
Major Depressive Disorder - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 36
Major Depressive Disorder - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 37
Major Depressive Disorder - Pipeline by Neurocrine Biosciences, Inc., H1 2014 38
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H1 2014 39
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H1 2014 40
Major Depressive Disorder - Pipeline by OPKO Health, Inc., H1 2014 41
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H1 2014 42
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H1 2014 43
Major Depressive Disorder - Pipeline by e-Therapeutics plc, H1 2014 44
Major Depressive Disorder - Pipeline by Intas Pharmaceuticals Ltd., H1 2014 45
Major Depressive Disorder - Pipeline by Angelini Group, H1 2014 46
Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 47
Major Depressive Disorder - Pipeline by Dart NeuroScience LLC, H1 2014 48
Major Depressive Disorder - Pipeline by M's Science Corporation, H1 2014 49
Major Depressive Disorder - Pipeline by BrainCells Inc., H1 2014 50
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 51
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 52
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H1 2014 53
Major Depressive Disorder - Pipeline by Euthymics Bioscience, Inc., H1 2014 54
Major Depressive Disorder - Pipeline by Naurex, Inc., H1 2014 55
Major Depressive Disorder - Pipeline by PharmaNeuroBoost NV, H1 2014 56
Major Depressive Disorder - Pipeline by NeurOp Corporation, H1 2014 57
Major Depressive Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2014 58
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H1 2014 59
Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 60
Major Depressive Disorder - Pipeline by BRAINco Biopharma, S.L., H1 2014 61
Major Depressive Disorder - Pipeline by Bionure, H1 2014 62
Major Depressive Disorder - Pipeline by Cerecor Inc., H1 2014 63
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H1 2014 64
Major Depressive Disorder - Pipeline by Aniona ApS, H1 2014 65
Assessment by Monotherapy Products, H1 2014 66
Assessment by Combination Products, H1 2014 67
Number of Products by Stage and Target, H1 2014 70
Number of Products by Stage and Mechanism of Action, H1 2014 74
Number of Products by Stage and Route of Administration, H1 2014 78
Number of Products by Stage and Molecule Type, H1 2014 81
Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H1 2014 153
Major Depressive Disorder - Dormant Projects, H1 2014 181
Major Depressive Disorder - Dormant Projects (Contd..1), H1 2014 182
Major Depressive Disorder - Dormant Projects (Contd..2), H1 2014 183
Major Depressive Disorder - Dormant Projects (Contd..3), H1 2014 184
Major Depressive Disorder - Dormant Projects (Contd..4), H1 2014 185
Major Depressive Disorder - Discontinued Products, H1 2014 186
Major Depressive Disorder - Discontinued Products (Contd..1), H1 2014 187
Major Depressive Disorder - Discontinued Products (Contd..2), H1 2014 188
List of Figures
Number of Products under Development for Major Depressive Disorder, H1 2014 14
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Assessment by Monotherapy Products, H1 2014 66
Assessment by Combination Products, H1 2014 67
Number of Products by Top 10 Target, H1 2014 68
Number of Products by Stage and Top 10 Target, H1 2014 69
Number of Products by Top 10 Mechanism of Action, H1 2014 72
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 73
Number of Products by Top 10 Route of Administration, H1 2014 76
Number of Products by Stage and Top 10 Route of Administration, H1 2014 77
Number of Products by Top 10 Molecule Type, H1 2014 79
Number of Products by Stage and Top 10 Molecule Type, H1 2014 80
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Major Depressive Disorder Overview 9
Therapeutics Development 10
Pipeline Products for Major Depressive Disorder - Overview 10
Pipeline Products for Major Depressive Disorder - Comparative Analysis 11
Major Depressive Disorder - Therapeutics under Development by Companies 12
Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 16
Major Depressive Disorder - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Major Depressive Disorder - Products under Development by Companies 22
Major Depressive Disorder - Products under Investigation by Universities/Institutes 26
Major Depressive Disorder - Companies Involved in Therapeutics Development 27
Johnson & Johnson 27
F. Hoffmann-La Roche Ltd. 28
AstraZeneca PLC 29
Eli Lilly and Company 30
Alkermes Plc 31
Dainippon Sumitomo Pharma Co., Ltd. 32
Taisho Pharmaceutical Co., Ltd. 33
Neurocrine Biosciences, Inc. 34
Richter Gedeon Nyrt. 35
H. Lundbeck A/S 36
OPKO Health, Inc. 37
Neuralstem, Inc. 38
Suven Life Sciences Ltd. 39
e-Therapeutics plc 40
Intas Pharmaceuticals Ltd. 41
Angelini Group 42
Fabre-Kramer Pharmaceuticals, Inc. 43
Dart NeuroScience LLC 44
M's Science Corporation 45
BrainCells Inc. 46
Otsuka Holdings Co., Ltd. 47
Reviva Pharmaceuticals Inc. 48
Luye Pharma Group Ltd. 49
Euthymics Bioscience, Inc. 50
Naurex, Inc. 51
PharmaNeuroBoost NV 52
NeurOp Corporation 53
Edgemont Pharmaceuticals, LLC 54
Methylation Sciences Inc. 55
Sunovion Pharmaceuticals Inc. 56
BRAINco Biopharma, S.L. 57
Bionure 58
Cerecor Inc. 59
nLife Therapeutics, S.L. 60
Aniona ApS 61
Major Depressive Disorder - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 72
Assessment by Molecule Type 75
Drug Profiles 78
vortioxetine - Drug Profile 78
vortioxetine - Drug Profile 80
lurasidone hydrochloride - Drug Profile 82
brexpiprazole - Drug Profile 84
cariprazine - Drug Profile 86
TGFK-07AD - Drug Profile 88
(pipamperone + citalopram) - Drug Profile 89
INASTR-001 - Drug Profile 91
trazodone hydrochloride - Drug Profile 92
(aripiprazole + sertraline) - Drug Profile 93
amitifadine - Drug Profile 95
Rellidep - Drug Profile 97
edivoxetine - Drug Profile 98
verucerfont - Drug Profile 100
RG-1578 - Drug Profile 102
TGBA-01AD - Drug Profile 104
SCH-900978 - Drug Profile 105
tramadol - Drug Profile 106
RG-7090 - Drug Profile 108
cutamesine - Drug Profile 109
GLYX-13 - Drug Profile 111
CERC-301 - Drug Profile 113
(samidorphan + buprenorphine hydrochloride) - Drug Profile 114
LY-2940094 - Drug Profile 115
HT-2157 - Drug Profile 116
esketamine - Drug Profile 117
MSI-195 - Drug Profile 118
diazoxide - Drug Profile 119
tedatioxetine - Drug Profile 120
BCI-632 - Drug Profile 122
AN-788 - Drug Profile 124
NSI-189 - Drug Profile 125
DSP-1053 - Drug Profile 126
BCI-838 - Drug Profile 127
BCI-1038 - Drug Profile 129
BCI-1206 - Drug Profile 130
BCI-1283 - Drug Profile 131
NRX-1074 - Drug Profile 132
SEP-363856 - Drug Profile 133
LY-03005 - Drug Profile 134
NSI-189 - Drug Profile 135
NRX-1050 - Drug Profile 136
SUVN-911 - Drug Profile 137
NR2B Program For Major Depression - Drug Profile 138
NLF-NEU - Drug Profile 139
Major Depression Program - Drug Profile 140
BN-201 - Drug Profile 141
Ketamine Metabolites - Drug Profile 142
BN-204 - Drug Profile 143
BN-206 - Drug Profile 144
RP-5063 - Drug Profile 145
EDG-005 - Drug Profile 146
Drug For Depression - Drug Profile 147
BN-205 - Drug Profile 148
Major Depressive Disorder - Recent Pipeline Updates 149
Major Depressive Disorder - Dormant Projects 177
Major Depressive Disorder - Discontinued Products 182
Major Depressive Disorder - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 196
Disclaimer 196
List of Tables
Number of Products under Development for Major Depressive Disorder, H1 2014 14
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Comparative Analysis by Unknown Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Development by Companies, H1 2014 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2014 30
Major Depressive Disorder - Pipeline by Johnson & Johnson, H1 2014 31
Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 32
Major Depressive Disorder - Pipeline by AstraZeneca PLC, H1 2014 33
Major Depressive Disorder - Pipeline by Eli Lilly and Company, H1 2014 34
Major Depressive Disorder - Pipeline by Alkermes Plc, H1 2014 35
Major Depressive Disorder - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 36
Major Depressive Disorder - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 37
Major Depressive Disorder - Pipeline by Neurocrine Biosciences, Inc., H1 2014 38
Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H1 2014 39
Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H1 2014 40
Major Depressive Disorder - Pipeline by OPKO Health, Inc., H1 2014 41
Major Depressive Disorder - Pipeline by Neuralstem, Inc., H1 2014 42
Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H1 2014 43
Major Depressive Disorder - Pipeline by e-Therapeutics plc, H1 2014 44
Major Depressive Disorder - Pipeline by Intas Pharmaceuticals Ltd., H1 2014 45
Major Depressive Disorder - Pipeline by Angelini Group, H1 2014 46
Major Depressive Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 47
Major Depressive Disorder - Pipeline by Dart NeuroScience LLC, H1 2014 48
Major Depressive Disorder - Pipeline by M's Science Corporation, H1 2014 49
Major Depressive Disorder - Pipeline by BrainCells Inc., H1 2014 50
Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 51
Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 52
Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H1 2014 53
Major Depressive Disorder - Pipeline by Euthymics Bioscience, Inc., H1 2014 54
Major Depressive Disorder - Pipeline by Naurex, Inc., H1 2014 55
Major Depressive Disorder - Pipeline by PharmaNeuroBoost NV, H1 2014 56
Major Depressive Disorder - Pipeline by NeurOp Corporation, H1 2014 57
Major Depressive Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2014 58
Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H1 2014 59
Major Depressive Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 60
Major Depressive Disorder - Pipeline by BRAINco Biopharma, S.L., H1 2014 61
Major Depressive Disorder - Pipeline by Bionure, H1 2014 62
Major Depressive Disorder - Pipeline by Cerecor Inc., H1 2014 63
Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H1 2014 64
Major Depressive Disorder - Pipeline by Aniona ApS, H1 2014 65
Assessment by Monotherapy Products, H1 2014 66
Assessment by Combination Products, H1 2014 67
Number of Products by Stage and Target, H1 2014 70
Number of Products by Stage and Mechanism of Action, H1 2014 74
Number of Products by Stage and Route of Administration, H1 2014 78
Number of Products by Stage and Molecule Type, H1 2014 81
Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H1 2014 153
Major Depressive Disorder - Dormant Projects, H1 2014 181
Major Depressive Disorder - Dormant Projects (Contd..1), H1 2014 182
Major Depressive Disorder - Dormant Projects (Contd..2), H1 2014 183
Major Depressive Disorder - Dormant Projects (Contd..3), H1 2014 184
Major Depressive Disorder - Dormant Projects (Contd..4), H1 2014 185
Major Depressive Disorder - Discontinued Products, H1 2014 186
Major Depressive Disorder - Discontinued Products (Contd..1), H1 2014 187
Major Depressive Disorder - Discontinued Products (Contd..2), H1 2014 188
List of Figures
Number of Products under Development for Major Depressive Disorder, H1 2014 14
Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Assessment by Monotherapy Products, H1 2014 66
Assessment by Combination Products, H1 2014 67
Number of Products by Top 10 Target, H1 2014 68
Number of Products by Stage and Top 10 Target, H1 2014 69
Number of Products by Top 10 Mechanism of Action, H1 2014 72
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 73
Number of Products by Top 10 Route of Administration, H1 2014 76
Number of Products by Stage and Top 10 Route of Administration, H1 2014 77
Number of Products by Top 10 Molecule Type, H1 2014 79
Number of Products by Stage and Top 10 Molecule Type, H1 2014 80
